Analysing the behaviour of this gene, not at a single time point, but throughout the various stages, Chang et al. (2013) suggested that the differential expression profile of NRF2 in tumour versus normal tissue could be an interesting new target for CRC treatment [49]. This evidence concerns the gene NFE2L2 and colorectal carcinoma.